President Trump announced Tuesday that imported generic drugs will face zero tariffs until August 2028, then jump to 100% — and 200% a year later — unless pharmaceutical companies move manufacturing to American soil.
The two-year grace period starting August 1 gives drugmakers time to build U.S. facilities before what Trump called “a penalty” hits companies that stay overseas. Nearly every prescription Americans fill uses generic drugs, most manufactured abroad through tangled global supply chains.
The Math Problem Facing Drugmakers
Building pharmaceutical plants in the United States costs far more than operating overseas facilities, and nearly all raw materials would still come from foreign suppliers. Deborah Elms, head of trade policy at the Hinrich Foundation, questioned whether even a 200% tariff changes the underlying economics.
Generic drugs keep prescription costs low for millions of American families. The complex ownership structures and international manufacturing networks that produce them developed over decades as companies chased lower costs.
What Happens to Your Medicine Costs
If companies don’t relocate production by the 2028 deadline, Americans could face sharply higher prices at the pharmacy counter. The tariffs would apply to imports, forcing either massive price increases or a scrambled rebuild of domestic manufacturing capacity.
Trump’s strategy aims to restore American pharmaceutical independence, reducing reliance on foreign suppliers that proved unreliable during recent supply chain disruptions. But the timeline gives companies less than two years to make multibillion-dollar plant construction decisions.
The announcement fits Trump’s broader most-favored-nation pricing push, which pressures drugmakers to charge Americans no more than patients pay in other wealthy countries. Combined with the tariff threat, the policies reshape how pharmaceutical companies price and produce medications for the U.S. market.
Watch whether major generic manufacturers announce U.S. plant construction before the grace period ends. Their decisions will determine whether your prescription costs drop from domestic competition or spike from tariff-inflated imports.
Key Points
- Generic drug imports face zero tariffs until August 2028, then 100% tariffs, rising to 200% in 2029
- Trump’s timeline gives pharmaceutical companies two years to relocate manufacturing to the United States
- Building U.S. drug plants costs far more than overseas facilities and still requires foreign raw materials
https://www.cnbc.com/2026/07/22/trump-generic-drugs-tariffs-medicine-trade-.html – July 22, 2026
